New York, New York--(Newsfile Corp. - July 17, 2026) - Kaplan Fox &amp; Kilsheimer LLP is investigating potential securities violations against Medline Inc. (&#34;Medline&#34; or the &#34;Company&#34;)

<p>New York, New York--(Newsfile Corp. - July 17, 2026) - <a href="https://api.newsfilecorp.com/redirect/rpbephqKVg">Kaplan Fox &#38; Kilsheimer LLP</a> is investigating potential securities violations against Medline Inc. ("Medline" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/MDLN">MDLN</a>).</p><p style="text-align: center;"><a href="https://api.newsfilecorp.com/redirect/VvWzvhY0Zo">CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION</a></p><p><b>If you are a Medline investor and have suffered losses, or if you have information that could assist in the Medline investigation, you may </b><a href="https://api.newsfilecorp.com/redirect/zAbrAUyXmX"><b>CLICK HERE</b></a><b> to contact us. You may also contact Kaplan Fox by emailing </b><a href="mailto:pmayer@kaplanfox.com"><b>pmayer@kaplanfox.com</b></a><b> or by calling (646) 315-9003.</b></p><p>On June 2, 2026, the Federal Drug Administration ("FDA") published a warning letter dated May 28, 2026 addressed to Medline summarizing "significant violations of Current Good Manufacturing Practice regulations for finished pharmaceuticals[.]" The FDA further states that Medline "failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications."</p><p>Following this news, the price of Medline stock fell $2.56 per share, or 7.16%, to close at $33.19 per share on June 2, 2026.</p><p>According to a June 3, 2026 <i>Reuters </i>article, the latest FDA warning letter relates to "violations of manufacturing quality standards" and is "the second such action against the [C]ompany in two months."  Further, the <i>Reuters </i>article states that according to the FDA, "the Company failed to thoroughly investigate microbial contamination incidents in finished drug products and also cited inadequate cleaning practices."</p><p><b>WHY CONTACT KAPLAN FOX?</b></p><p>Kaplan Fox &#38; Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.</p><p>Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in <i>In re Bank of America</i>-the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act-$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in <i>ATRS v. Allianz Global Investors</i>, and a $475 million settlement in <i>In re Merrill Lynch</i>.</p><p>For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.</p><p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.</p><p>If you have any questions about this investigation, please contact:</p><div id="contactInfo"><p><b>CONTACT:</b></p><p>Pamela A. Mayer<br /><a href="https://api.newsfilecorp.com/redirect/4YaJYcW574">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />800 Third Avenue, 38th Floor<br />New York, New York 10022<br />(646) 315-9003<br /><a href="mailto:pmayer@kaplanfox.com">pmayer@kaplanfox.com</a></p><p>Laurence D. King<br /><a href="https://api.newsfilecorp.com/redirect/jNWRNFrByv">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />1999 Harrison Street, Suite 1501<br />Oakland, California 94612<br />(415) 772-4704<br /><a href="mailto:lking@kaplanfox.com">lking@kaplanfox.com</a></p></div><p>Contacting or submitting information to Kaplan Fox &#38; Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.</p><p><a href="https://api.newsfilecorp.com/redirect/vEbAESDJv4">https://www.kaplanfox.com/case/medline-inc-class-action-alert-learn-more-now/</a></p><p id="corporateNewsLogoContainer"><img src="https://images.newsfilecorp.com/files/12532/305627_d303d00254eeaa85_logo.jpg" id="corporateNewsLogo" alt="Corporate Logo" /></p><p id="corporateLinkBack">To view the source version of this press release, please visit <a href="https://api.newsfilecorp.com/redirect/JkoxkhALe1">https://www.newsfilecorp.com/release/305627</a></p><p><img src="https://api.newsfilecorp.com/newsinfo/305627/197" alt="" /></p>

MDLN

Kaplan Fox Alerts Medline Inc. (MDLN) Investors to an Investigation of Potential Securities Law Violations

Medline Faces FDA Violations and Securities Investigation Tied to MDLN Stock

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>New York, New York--(Newsfile Corp. - July 17, 2026) - Kaplan Fox &amp;amp; Kilsheimer LLP is investigating potential securities violations against Medline Inc. (&amp;#34;Medline&amp;#34; or the &amp;#34;Company&amp;#34;)</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Medline is facing regulatory risk after an FDA CGMP warning letter dated May 28, 2026, triggering a 7.2% stock drop on June 2 and Reuters noting a second FDA action in two months. Kaplan Fox is investigating potential securities violations, signaling heightened legal exposure that could pressure MDLN’s valuation and liquidity if litigation or fines materialize.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Kaplan Fox investigating MDLN for potential securities violations.</li><li>FDA warning letter cites CGMP violations dated May 28, 2026.</li><li>MDLN stock closed at $33.19 on June 2, 2026, down 7.16%.</li><li>Reuters notes second FDA action in two months; microbial contamination, cleaning cited.</li><li>Law firm touts litigation track record and invites investor communication.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Medline Inc. (MDLN)</strong>: Subject of FDA CGMP violations; faces potential securities-related action.</li><li><strong>Kaplan Fox &amp; Kilsheimer LLP (N/A)</strong>: Securities investigation firm behind the alert; not a public company.</li><li><strong>FDA (N/A)</strong>: Issued warning letter on CGMP violations impacting Medline&#039;s manufacturing compliance.</li><li><strong>Reuters (N/A)</strong>: Reporting on FDA actions; contributes to market visibility of MDLN regulatory risk.</li></ul>
  </section>

  <section data-block="category">
    <h3>Legal</h3>
    <p>Category: Legal. The piece centers on a regulatory inquiry and a securities-law investigation related to MDLN, aligning with legal risk and potential impact on fundamentals and valuation.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>FDA CGMP warning letter to Medline cited; regulatory risk persists.</li><li>MDLN stock fell 7.16% to $33.19 on June 2, 2026.</li><li>Reuters reports second FDA action against Medline in two months.</li><li>Kaplan Fox launching a securities investigation adds litigation risk.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>FDA warning letter to Medline for CGMP violations dated May 28, 2026 (publicized June 2, 2026).</li><li>MDLN stock closed at $33.19 on June 2, 2026, down 7.16%.</li><li>Trade data: MDLN fell by $2.56 per share on June 2, 2026.</li><li>Reuters confirms this is the second FDA action against Medline in two months, citing microbial contamination and inadequate cleaning.</li><li>Kaplan Fox &amp; Kilsheimer LLP investigating potential MDLN securities violations.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Bearish near-term for MDLN as regulatory and legal actions unfold over weeks.</p>
  </section>
</section>


<p>New York, New York--(Newsfile Corp. - July 17, 2026) - <a href="https://api.newsfilecorp.com/redirect/rpbephqKVg">Kaplan Fox &#38; Kilsheimer LLP</a> is investigating potential securities violations against Medline Inc. ("Medline" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/MDLN">MDLN</a>).</p><p style="text-align: center;"><a href="https://api.newsfilecorp.com/redirect/VvWzvhY0Zo">CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION</a></p><p><b>If you are a Medline investor and have suffered losses, or if you have information that could assist in the Medline investigation, you may </b><a href="https://api.newsfilecorp.com/redirect/zAbrAUyXmX"><b>CLICK HERE</b></a><b> to contact us. You may also contact Kaplan Fox by emailing </b><a href="mailto:pmayer@kaplanfox.com"><b>pmayer@kaplanfox.com</b></a><b> or by calling (646) 315-9003.</b></p><p>On June 2, 2026, the Federal Drug Administration ("FDA") published a warning letter dated May 28, 2026 addressed to Medline summarizing "significant violations of Current Good Manufacturing Practice regulations for finished pharmaceuticals[.]" The FDA further states that Medline "failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications."</p><p>Following this news, the price of Medline stock fell $2.56 per share, or 7.16%, to close at $33.19 per share on June 2, 2026.</p><p>According to a June 3, 2026 <i>Reuters </i>article, the latest FDA warning letter relates to "violations of manufacturing quality standards" and is "the second such action against the [C]ompany in two months."  Further, the <i>Reuters </i>article states that according to the FDA, "the Company failed to thoroughly investigate microbial contamination incidents in finished drug products and also cited inadequate cleaning practices."</p><p><b>WHY CONTACT KAPLAN FOX?</b></p><p>Kaplan Fox &#38; Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.</p><p>Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in <i>In re Bank of America</i>-the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act-$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in <i>ATRS v. Allianz Global Investors</i>, and a $475 million settlement in <i>In re Merrill Lynch</i>.</p><p>For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.</p><p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.</p><p>If you have any questions about this investigation, please contact:</p><div id="contactInfo"><p><b>CONTACT:</b></p><p>Pamela A. Mayer<br /><a href="https://api.newsfilecorp.com/redirect/4YaJYcW574">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />800 Third Avenue, 38th Floor<br />New York, New York 10022<br />(646) 315-9003<br /><a href="mailto:pmayer@kaplanfox.com">pmayer@kaplanfox.com</a></p><p>Laurence D. King<br /><a href="https://api.newsfilecorp.com/redirect/jNWRNFrByv">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />1999 Harrison Street, Suite 1501<br />Oakland, California 94612<br />(415) 772-4704<br /><a href="mailto:lking@kaplanfox.com">lking@kaplanfox.com</a></p></div><p>Contacting or submitting information to Kaplan Fox &#38; Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.</p><p><a href="https://api.newsfilecorp.com/redirect/vEbAESDJv4">https://www.kaplanfox.com/case/medline-inc-class-action-alert-learn-more-now/</a></p><p id="corporateNewsLogoContainer"><img src="https://images.newsfilecorp.com/files/12532/305627_d303d00254eeaa85_logo.jpg" id="corporateNewsLogo" alt="Corporate Logo" /></p><p id="corporateLinkBack">To view the source version of this press release, please visit <a href="https://api.newsfilecorp.com/redirect/JkoxkhALe1">https://www.newsfilecorp.com/release/305627</a></p><p><img src="https://api.newsfilecorp.com/newsinfo/305627/197" alt="" /></p>

Medline is facing regulatory risk after an FDA CGMP warning letter dated May 28, 2026, triggering a 7.2% stock drop on June 2 and Reuters noting a second FDA action in two months. Kaplan Fox is investigating potential securities violations, signaling heightened legal exposure that could pressure MDLN’s valuation and liquidity if litigation or fines materialize.

Kaplan Fox Alerts Medline Inc. (MDLN) Investors to an Investigation of Potential Securities Law Violations

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Legal

Related News